​

Curanex Pharmaceuticals Stock (NASDAQ:CURX)

FinancialsChart

Previous Close

$0.46

52W Range

$0.38 - $9.18

50D Avg

$0.68

200D Avg

$2.10

Market Cap

$12.89M

Avg Vol (3M)

$1.82M

Beta

-

Div Yield

-

CURX Company Profile

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. The company was founded in 1996 and is headquartered in Jericho, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

-

IPO Date

Aug 26, 2025

Website

CURX Performance

CURX Financial Summary

Dec 24Dec 23Dec 22
Revenue--$26.00K
Operating Income$-365.06K$-19.30K$-20.23K
Net Income$-361.51K$-19.20K$-20.23K
EBITDA$-290.39K$-17.48K$925.00
Basic EPS$-0.01-$-0.02
Diluted EPS$-0.01-$-0.02

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
LGVNLongeveron Inc.
DAREDaré Bioscience, Inc.
ASBPAspire Biopharma Holdings, Inc.
CUPRCuprina Holdings (Cayman) Limited Class A Ordinary Shares
HOTHHoth Therapeutics, Inc.
BCTXBriaCell Therapeutics Corp.
CRISCuris, Inc.
PULMPulmatrix, Inc.
LPTXLeap Therapeutics, Inc.
PALIPalisade Bio, Inc.